These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 30444204)

  • 21. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endocan Serum Levels in Patients with Non-Alcoholic Fatty Liver Disease with or without Type 2 Diabetes Mellitus: A Pilot Study.
    Dallio M; Masarone M; Caprio GG; Di Sarno R; Tuccillo C; Sasso FC; Persico M; Loguercio C; Federico A
    J Gastrointestin Liver Dis; 2017 Sep; 26(3):261-268. PubMed ID: 28922438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of high sensitivity C-reaction protein in non-insulin dependent diabetes mellitus patients with non-alcoholic fatty liver disease.
    Bi Y; Min M; Shen W; Deng P; Du Q; Dong M; Liu Y
    Int J Clin Exp Pathol; 2015; 8(7):8494-9. PubMed ID: 26339423
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Screening for non-alcoholic fatty liver disease in children and adolescents with type 1 diabetes mellitus: a cross-sectional analysis.
    Kummer S; Klee D; Kircheis G; Friedt M; Schaper J; Häussinger D; Mayatepek E; Meissner T
    Eur J Pediatr; 2017 Apr; 176(4):529-536. PubMed ID: 28213828
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes.
    Freemark M; Bursey D
    Pediatrics; 2001 Apr; 107(4):E55. PubMed ID: 11335776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels.
    Portillo-Sanchez P; Bril F; Maximos M; Lomonaco R; Biernacki D; Orsak B; Subbarayan S; Webb A; Hecht J; Cusi K
    J Clin Endocrinol Metab; 2015 Jun; 100(6):2231-8. PubMed ID: 25885947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease.
    Tian F; Zheng Z; Zhang D; He S; Shen J
    Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30473540
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An update on nonalcoholic fatty liver disease.
    Provencher DM
    JAAPA; 2014 Jul; 27(7):18-22. PubMed ID: 24901731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of glucagon-to-insulin ratio and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.
    Moh Moh MA; Jung CH; Lee B; Choi D; Kim BY; Kim CH; Kang SK; Mok JO
    Diab Vasc Dis Res; 2019 Mar; 16(2):186-195. PubMed ID: 30428692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanism of action of gypenosides on type 2 diabetes and non-alcoholic fatty liver disease in rats.
    He Q; Li JK; Li F; Li RG; Zhan GQ; Li G; Du WX; Tan HB
    World J Gastroenterol; 2015 Feb; 21(7):2058-66. PubMed ID: 25717238
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-alcoholic fatty liver disease (NAFLD) and significant hepatic fibrosis defined by non-invasive assessment in patients with type 2 diabetes.
    Sobhonslidsuk A; Pulsombat A; Kaewdoung P; Petraksa S
    Asian Pac J Cancer Prev; 2015; 16(5):1789-94. PubMed ID: 25773826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Correlation analysis of gut microbiota and biochemical indexes in patients with non-alcoholic fatty liver disease].
    Ren SM; Mei L; Huang H; Cao SF; Zhao RH; Zheng PY
    Zhonghua Gan Zang Bing Za Zhi; 2019 May; 27(5):369-375. PubMed ID: 31177662
    [No Abstract]   [Full Text] [Related]  

  • 33. Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound.
    Petrović G; Bjelaković G; Benedeto-Stojanov D; Nagorni A; Brzački V; Marković-Živković B
    Vojnosanit Pregl; 2016 Oct; 73(10):910-20. PubMed ID: 29327896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
    Cusi K
    Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum 25-hydroxyvitamin D, non-alcoholic fatty liver disease and type 2 diabetes.
    Afarideh M; Ghajar A; Noshad S; Saadat M; Khajeh E; Esteghamati A
    Nutr Metab Cardiovasc Dis; 2017 Jan; 27(1):93-95. PubMed ID: 27986351
    [No Abstract]   [Full Text] [Related]  

  • 36. Is HOMA-IR a potential screening test for non-alcoholic fatty liver disease in adults with type 2 diabetes?
    Gutierrez-Buey G; Núñez-Córdoba JM; Llavero-Valero M; Gargallo J; Salvador J; Escalada J
    Eur J Intern Med; 2017 Jun; 41():74-78. PubMed ID: 28283346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergistic increase in cardiovascular risk in diabetes mellitus with nonalcoholic fatty liver disease: a meta-analysis.
    Zhou YY; Zhou XD; Wu SJ; Hu XQ; Tang B; Poucke SV; Pan XY; Wu WJ; Gu XM; Fu SW; Zheng MH
    Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):631-636. PubMed ID: 29351115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of effects of obesity and non-alcoholic fatty liver disease on incidence of type 2 diabetes mellitus.
    Li WD; Fu KF; Li GM; Lian YS; Ren AM; Chen YJ; Xia JR
    World J Gastroenterol; 2015 Aug; 21(32):9607-13. PubMed ID: 26327768
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.
    Federico A; Zulli C; de Sio I; Del Prete A; Dallio M; Masarone M; Loguercio C
    World J Gastroenterol; 2014 Dec; 20(45):16841-57. PubMed ID: 25492998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-alcoholic fatty liver disease (NAFLD) and 10-year risk of cardiovascular diseases.
    Motamed N; Rabiee B; Poustchi H; Dehestani B; Hemasi GR; Khonsari MR; Maadi M; Saeedian FS; Zamani F
    Clin Res Hepatol Gastroenterol; 2017 Feb; 41(1):31-38. PubMed ID: 27597641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.